Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data

Authors

  • Sibel Oyucu Orhan Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey https://orcid.org/0000-0001-8217-3471
  • Ahmet Bilgehan Sahin Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey https://orcid.org/0000-0002-7846-0870
  • Erdem Cubukcu Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey
  • Adem Deligonul Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey https://orcid.org/0000-0002-3669-6391
  • Birol Ocak Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey https://orcid.org/0000-0001-7537-1699
  • Bedrettin Orhan Division of Hematology, Department of Internal Medicine, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey https://orcid.org/0000-0003-3970-2344
  • Turkkan Evrensel Department of Medical Oncology, Faculty of Medicine, Bursa Uludag University, Bursa, Turkey https://orcid.org/0000-0002-9732-5340

DOI:

https://doi.org/10.17305/bjbms.2020.5329

Keywords:

Kaposi sarcoma, chemotherapy, pegylated liposomal doxorubicin, paclitaxel

Abstract

Kaposi sarcoma is a rare disease and there is a gap in the literature about which chemotherapeutics should be applied, especially for the classical type. We aimed to present our institutional data on the demographic characteristics, treatment, and treatment efficacy in 16 Kaposi sarcoma (KS) patients treated with chemotherapy. We retrospectively analyzed the demographic and clinical characteristics, and the chemotherapeutic agents administered to the 16 KS patients diagnosed in our center and treated with chemotherapy, based on the medical records obtained. The median age, gender, type of KS, site of involvement, cytotoxic agents administered, progression-free survival (PFS), overall survival (OS), objective response rate (ORR), disease control rate (DCR), and safety profiles of the patients were evaluated. The median age at disease onset was 61.07 years (range, 39.4–85.8 years). Among the patients, 1 had immunosuppression-related KS, 4 had AIDS-related KS, and 11 had classical KS. In the first-line cytotoxic therapy, 7 patients received pegylated-liposomal doxorubicin (PLD), 6 patients received paclitaxel, 2 patients received oral etoposide, and 1 patient received the adriamycin, bleomycin, and vincristine regimen. In the Kaplan–Meier analysis, the PFS was 39.9 months (95% CI, 7.7–72.0). In the first-line setting, a significant difference in terms of PFS was observed between the PLD- and paclitaxel-treated groups (not reached vs. 12.8 months, p = 0.033). The OS was 66.1 months (95% CI, 30.2–102.0). The ORR of the 16 patients was 43.8%, and their DCR was 81.3%. No grade 3 or 4 toxicity was observed. This retrospective study showed that PLD seems better than paclitaxel in terms of PFS and response rates and it has shown to have a good safety profile in KS patients.

Downloads

Download data is not yet available.
Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data

Downloads

Additional Files

Published

01-12-2021

Issue

Section

Translational and Clinical Research

Categories

How to Cite

1.
Efficacy of chemotherapeutics in classic and non-classic Kaposi sarcoma: A single-center retrospective real-world data. Biomol Biomed [Internet]. 2021 Dec. 1 [cited 2024 Apr. 23];21(6):746-51. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/5329